WO2010014830A3 - Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation - Google Patents

Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2010014830A3
WO2010014830A3 PCT/US2009/052282 US2009052282W WO2010014830A3 WO 2010014830 A3 WO2010014830 A3 WO 2010014830A3 US 2009052282 W US2009052282 W US 2009052282W WO 2010014830 A3 WO2010014830 A3 WO 2010014830A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vegf
bind vegf
peptide therapeutics
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/052282
Other languages
English (en)
Other versions
WO2010014830A4 (fr
WO2010014830A2 (fr
Inventor
Don Low
Gregor Schurmann
Andreas Jungbluth
Michael Mersmann
Tamas Blandl
Katherine E. Hoover
Eberhard Schneider
Ying Hu
Peter Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmix Therapeutics LLC
Original Assignee
Cosmix Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmix Therapeutics LLC filed Critical Cosmix Therapeutics LLC
Priority to EP09803601A priority Critical patent/EP2324048A2/fr
Publication of WO2010014830A2 publication Critical patent/WO2010014830A2/fr
Publication of WO2010014830A3 publication Critical patent/WO2010014830A3/fr
Publication of WO2010014830A4 publication Critical patent/WO2010014830A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des peptides et des mimétiques de ceux-ci qui se lient à VEGF. Dans des modes de réalisation préférés, les peptides de l'invention sont des isomères optiques de type D qui peuvent se lier à VEGF et qui peuvent inhiber ou réduire l'activité biologique de VEGF.
PCT/US2009/052282 2008-07-30 2009-07-30 Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation Ceased WO2010014830A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09803601A EP2324048A2 (fr) 2008-07-30 2009-07-30 Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8490108P 2008-07-30 2008-07-30
US61/084,901 2008-07-30

Publications (3)

Publication Number Publication Date
WO2010014830A2 WO2010014830A2 (fr) 2010-02-04
WO2010014830A3 true WO2010014830A3 (fr) 2010-05-27
WO2010014830A4 WO2010014830A4 (fr) 2010-07-22

Family

ID=41610962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052282 Ceased WO2010014830A2 (fr) 2008-07-30 2009-07-30 Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation

Country Status (3)

Country Link
US (1) US20100093624A1 (fr)
EP (1) EP2324048A2 (fr)
WO (1) WO2010014830A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638063A4 (fr) 2010-11-12 2014-04-23 Reflexion Pharmaceuticals Inc Banques peptidiques gb 1 et composés associés, et leurs procédés de criblage
EP2751135A4 (fr) * 2011-08-31 2015-06-03 Indi Molecular Inc Agents de capture spécifiques du vegf, compositions en contenant et leurs procédés d'utilisation et de production
WO2013082531A2 (fr) 2011-12-02 2013-06-06 Reflexion Pharmaceuticals Vaccins neutralisant la grippe a à large spectre et composés d-peptidiques et procédés de fabrication et d'utilisation de ceux-ci
WO2014140882A2 (fr) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Banques peptidiques à base d'un échafaudage et leurs procédés d'élaboration et de criblage
EP3003369A4 (fr) * 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un pyrophosphate
HRP20211561T8 (hr) 2014-06-12 2022-03-04 Ra Pharmaceuticals, Inc. Modulacija aktivnosti komplementa
EP3250230B9 (fr) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulateurs d'activité du complément
EP3294752B1 (fr) * 2015-05-12 2020-11-04 The Regents of the University of California Utilisation de peptides pour le traitement de l'inflammation et de la fibrose
EP3685847B1 (fr) 2015-12-16 2023-01-11 RA Pharmaceuticals, Inc. Modulateurs d'activité complémentaire
ES2903397T3 (es) 2015-12-30 2022-04-01 Marshall Univ Research Corporation Composiciones y métodos para tratar la retinopatía
TW201836634A (zh) 2016-12-07 2018-10-16 美商Ｒａ製藥公司 補體活性之調節劑
US20210061861A1 (en) * 2019-03-22 2021-03-04 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
CN114144433A (zh) * 2019-03-22 2022-03-04 反射制药有限公司 用于目标蛋白的多价d-肽化合物
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento
EP4643867A1 (fr) * 2024-04-30 2025-11-05 Eberhard Karls Universität Tübingen (Medizinische Fakultät) Proteine de liaison au vegf

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196754A1 (en) * 2000-03-31 2005-09-08 Drmanac Radoje T. Novel nucleic acids and polypeptides
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US20070044171A1 (en) * 2000-12-14 2007-02-22 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585353A (en) * 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
ES2290976T3 (es) * 1992-06-05 2008-02-16 The Scripps Research Institute D-proteina ligada y metodo para identificar compuestos que modulan la actividad de receptores.
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
MXPA04000564A (es) * 2001-07-20 2005-02-17 Univ Zuerich Composiciones y metodos para uso de agentes bioactivos derivados de aminoacidos sulfatados y sulfonados.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196754A1 (en) * 2000-03-31 2005-09-08 Drmanac Radoje T. Novel nucleic acids and polypeptides
US20070044171A1 (en) * 2000-12-14 2007-02-22 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides

Also Published As

Publication number Publication date
US20100093624A1 (en) 2010-04-15
EP2324048A2 (fr) 2011-05-25
WO2010014830A4 (fr) 2010-07-22
WO2010014830A2 (fr) 2010-02-04

Similar Documents

Publication Publication Date Title
WO2010014830A3 (fr) Produits thérapeutiques peptidiques qui se lient à vegf et leurs procédés d'utilisation
EA201001223A1 (ru) Стабилизированные белковые композиции
WO2009102421A3 (fr) Agents thérapeutiques cibles basés sur des protéines fabriquées qui se lient au récepteur de l’egf
BRPI0909084A2 (pt) Composição líquida, e, composto de peptídeo.
EP4491226A3 (fr) Variants fc optimisés
WO2010078945A3 (fr) Traitement du cancer
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2007082923A3 (fr) Utilisation de microbilles de proteines dans le domaine cosmetique
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
WO2010034032A3 (fr) Procédés pour préparer des compositions de polypeptide purifié
WO2011060206A3 (fr) Matière et procédés pour traiter ou prévenir des maladies associées à her-3
FR2941231B1 (fr) Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
WO2010034718A8 (fr) Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire
WO2006088888A3 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
WO2008089073A8 (fr) Banques combinatoires de séquences polypeptidiques conformationnellement contraintes
WO2007101698A3 (fr) Molecules modifiees destinees a promouvoir l'hematopoiese
WO2008156873A3 (fr) Mimétiques du peptide apo-ai
WO2008093058A3 (fr) Peptides et leur utilisation
WO2010014922A3 (fr) Marqueurs de purification de protéine et leurs utilisations
WO2008095622A3 (fr) Luciférase secrétée mluc7 et son utilisation
WO2009047513A3 (fr) Composé, utilisation et procédé
WO2007101146A3 (fr) Agonistes peptidiques sélectifs du récepteur vpac2
WO2007133828A3 (fr) Agonistes peptidiques sélectifs du récepteur vpac2
WO2009138494A3 (fr) Séquences d'acides aminés dirigées contre des récepteurs du type toll et polypeptides comprenant celles-ci pour le traitement de maladies apparentées aux récepteurs du type toll
WO2012090207A3 (fr) Peptides par1 et par2 de queue c et mimétiques peptidiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803601

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009803601

Country of ref document: EP